A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd.
Dren Bio
Merck Sharp & Dohme LLC
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Merck Sharp & Dohme LLC
University of California, Davis
University Health Network, Toronto
Ossium Health, Inc.
Dana-Farber Cancer Institute
Essen Biotech
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
NuCana plc
UNC Lineberger Comprehensive Cancer Center
OncoNano Medicine, Inc.
University Health Network, Toronto
UNC Lineberger Comprehensive Cancer Center
Young Adult Survivors United
Treeline Biosciences, Inc.
SciTech Development, Inc.
Ohio State University Comprehensive Cancer Center
Washington University School of Medicine
Incyte Corporation
Semmelweis University
Barbara Ann Karmanos Cancer Institute
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
City of Hope Medical Center
Novartis
Tempus AI
City of Hope Medical Center
Instituto de Investigación Biomédica de Salamanca
Region Skane
Cedars-Sinai Medical Center
National Cancer Institute (NCI)
Daiichi Sankyo
University Health Network, Toronto
VitaMed Research LLC
Columbia University
Kyowa Kirin Co., Ltd.
City of Hope Medical Center
Indiana University
Cedars-Sinai Medical Center
Pfizer
Sanguine Biosciences
Presage Biosciences
Eisai Inc.